Talking Medicines moves to capture pharma demand for better patient intelligence

Tern plc

Proposed changes to US pharmaceutical advertising rules could strengthen demand for the type of patient intelligence provided by Talking Medicines.

The US Food and Drug Administration added a proposal on transparency in direct-to-consumer advertising to its Unified Agenda in July 2026. At the same time, US Health and Human Services Secretary Robert F. Kennedy Jr. indicated that the existing “adequate provision” framework could be reviewed. Any tightening of the rules would put more pressure on pharmaceutical companies to get consumer-facing messaging right before campaigns are launched.

Talking Medicines DrugVoice platform uses artificial intelligence to analyse real-world healthcare conversations and identify what patients are saying about treatments, symptoms, unmet needs, misconceptions and concerns.

If pharmaceutical companies face stricter requirements around how products are presented to patients, they may need better evidence on what those patients understand, question and respond to before advertising is created. DrugVoice is designed to provide that information earlier in the process.

Instead of relying mainly on campaign performance data after launch, Talking Medicines is targeting the planning stage. Its technology is intended to help pharmaceutical brands and agencies shape messaging around actual patient conversations rather than assumptions.

Poorly judged messaging can create compliance risk, weaken campaign effectiveness and force companies to make changes after money has already been committed. Better intelligence at the start of the process can help reduce those risks.

Talking Medicines also combines Patient Intelligence with Healthcare Professional Intelligence. Patient data can show how people talk about treatments, what concerns them and where misunderstandings exist. Healthcare professional data can provide insight into prescribing priorities, clinical engagement and treatment adoption.

Bringing those perspectives together can help pharmaceutical companies make more informed decisions before committing to campaign strategy.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Search